RxDoctor Payments Data

Michael Switzer, MD

Vascular & Interventional Radiology · Sun City, AZNPI 1639309073

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,788 of the $7,679 with a category attached, or 88.4%. It is spread thinly across 30 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,493 and has fallen 74.8% since, to $628 in 2025.

$7,679in general payments, 2019–2025

Across 236 payments — averaging $32.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Angiodynamics, Inc.$1K
  • Nevro Corp.$1K
  • Abbott$532
  • Cardiovascular Systems Inc.$471
  • Boston Scientific$446
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$89212%
  • Food & beverage$6,78888%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,679 in reported general payments places this provider in the 65th percentile of 80 vascular & interventional radiology providers in Arizona.

See all vascular & interventional radiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,053,586
Medicare patients
366
Services billed
1,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban29$18,421
ClopidogrelClopidogrel Bisulfate91$772
Cilostazol18$298
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$53$18,42129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 80 vascular & interventional radiology providers in Arizona.

Other vascular & interventional radiology in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →